Global Pseudohypoaldosteronism Type 1 Market Size is Expected to Attain USD 49.50 Million by 2035 | CAGR of 4.63%
Category: HealthcareGlobal Pseudohypoaldosteronism Type 1 Market Size is Expected to Attain USD 49.50 Million by 2035
According to a Research Report Published by Spherical Insights & Consulting, The Global Pseudohypoaldosteronism Type 1 Market Size is Expected to Grow from USD 30.10 Million in 2024 to USD 49.50 Million by 2035, at a CAGR of 4.63% during the forecast period 2025-2035.
Get more details on this report -
Browse 210 Market Data Tables And 45 Figures Spread Through 190 Pages and In-Depth TOC On the " Global Pseudohypoaldosteronism Type 1 Market Size, Share, and COVID-19 Impact Analysis, By Type (Recessive and Dominant), By Diagnosis (Blood Test, Plasma Test, and Others), By Treatment (Sodium Supplement and Others), By End-Users (Hospitals, Specialty Clinics, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035. " Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/pseudohypoaldosteronism-type-1-market
The Pseudohypoaldosteronism Type 1 Market Size refers to the worldwide industry that focuses on diagnosing and managing a rare, life-threatening genetic salt-wasting disorder, driven by advancements in genetic testing and increasing awareness of pediatric endocrine conditions. Pseudohypoaldosteronism type 1 (PHA1) is a rare inherited disorder condition characterized by problems regulating the amount of sodium in the body, and severe resistance to the hormone aldosterone, which leads to neonatal salt wasting, hyponatremia, hyperkalemia, and metabolic acidosis. Innovation and market expansion are anticipated as a result of major players' expanding partnerships between clinical centres for clinical investigation. An increasing prevalence of rare genetic disorders, enhancing inclination towards early diagnosis and targeted treatment approaches are primarily driving the market. Additionally, increasing awareness among health professionals and increasing focus on rare disease management also contribute to enhancing the market growth. However, factors like limited awareness, cost of genetic testing, regulatory hurdles, and low accessibility of specialized healthcare centres, especially in the underdeveloped areas are hampering the market growth.
The recessive segment dominated the market with the largest share of over 50.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the type, the Pseudohypoaldosteronism Type 1 Market Size is divided into recessive and dominant. Among these, the recessive segment dominated the market with the largest share of over 50.0% in 2024 and is projected to grow at a substantial CAGR during the forecast period. The recessive PHA 1 gas severe, life-long, and multi-organ salt-wasting nature, and as per an MDPI study, it was found that in 164 genetically tested cases, 32.9% were recessive ENaC mutation, i.e., PHA1 b, often requiring much higher, intensive, and long-term care.
The blood test segment accounted for the largest share of around 50.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the diagnosis, the Pseudohypoaldosteronism Type 1 Market Size is divided into blood test, plasma test, and others. Among these, the blood test segment accounted for the largest share of around 50.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Blood test confirming the serum potassium, low serum sodium (hyponatremia), and metabolic acidosis, coupled with elevated plasma renin activity and high aldosterone levels.
The sodium supplement segment accounted for the largest share of around 45.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the treatment, the Pseudohypoaldosteronism Type 1 Market Size is divided into sodium supplement and others. Among these, the sodium supplement segment accounted for the largest share of around 45.0% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. Its established efficacy in correcting electrolyte imbalances and preventing severe dehydration episodes in patients, sodium supplementation remains the cornerstone of therapy, often combined with careful dietary management and regular monitoring.
The hospitals segment dominated the market with the largest share of over 55.1% in 2024 and is projected to grow at a substantial CAGR during the forecast period.
Based on the end-users, the Pseudohypoaldosteronism Type 1 Market Size is divided into hospitals, specialty clinics, and others. Among these, the hospitals segment dominated the market with the largest share of over 55.1% in 2024 and is projected to grow at a substantial CAGR during the forecast period. The segment specifically includes the Neonatal Intensive Care Unit (NICU) and Pediatric Intensive Care Unit (PICU). The upsurging focus on correcting life-threatening electrolyte imbalances and salt loss primarily through high-dose sodium chloride supplementation is driving the segmental market
Get more details on this report -
North America is expected to hold the majority share of the global Pseudohypoaldosteronism Type 1 Market Size during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of about 41.5% in the global Pseudohypoaldosteronism Type 1 Market Size during the forecast period. The United States is leading the North America Pseudohypoaldosteronism Type 1 Market Size, accounting for about 45.0% share in 2024, driven by increased awareness of rare genetic disorders and the presence of advanced healthcare infrastructure. North America has a robust market ecosystem that includes both increased awareness and advanced healthcare infrastructure. Further, the region's increased healthcare expenditure, strong R&D capabilities, and presence of key pharmaceutical industries that are focusing on rare disease therapies are promoting the North America Pseudohypoaldosteronism Type 1 Market Size.
Asia Pacific is anticipated to grow at the fastest pace of CAGR 6.2% in the global Pseudohypoaldosteronism Type 1 Market Size during the forecast period. India accounts for the dominant share in the Asia Pacific region, due to the country’s expanding healthcare infrastructure, adoption of genetic testing, and government initiatives supporting rare disease management. In the Asia Pacific Pseudohypoaldosteronism Type 1 Market Size, rising healthcare infrastructure, awareness program, and government programs for rare disease diagnosis and treatment initiatives are promoting the market.
Major vendors in the global Pseudohypoaldosteronism Type 1 Market Size are Sandoz AG, Pfizer Inc., Hikma Pharmaceuticals PLC, Merck & Co., Inc., Blueprint Genetics Oy, PreventionGenetics, Breda Genetics, Ultragenyx Pharmaceutical Inc., GeneDx, LLC, Invitae Corporation, Eurofins Scientific, Ambry Genetics, Fulgent Genetics, Quest Diagnostics, Thermo Fisher Scientific, Inc, Illumina, Inc., PerkinElmer, Labcorp, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In September 2025, A case report article was published on the title ‘Functional investigation of the γENaC G532S mutation presenting as mild PHA-1B3’.
- In January 2024, A case study report article was published entitled ‘Early molecular confirmation and sodium polystyrene sulfonate management of systemic pseudohypoaldosteronism type I’.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Pseudohypoaldosteronism Type 1 Market Size based on the below-mentioned segments:
Global Pseudohypoaldosteronism Type 1 Market Size, By Type
- Recessive
- Dominant
Global Pseudohypoaldosteronism Type 1 Market Size, By Diagnosis
- Blood Test
- Plasma Test
- Others
Global Pseudohypoaldosteronism Type 1 Market Size, By Treatment
- Sodium Supplement
- Others
Global Pseudohypoaldosteronism Type 1 Market Size, By End-Users
- Hospitals
- Specialty Clinics
- Others
Global Pseudohypoaldosteronism Type 1 Market Size, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?